Altesa BioSciences, Inc. — SEC Form D Filing
Altesa BioSciences, Inc. filed an SEC Form D on February 23, 2026, reporting $75.00M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- February 23, 2026
- Amount reported
- $75.00M
- Round stage
- Seed
- Industry
- Pharmaceuticals
- Website
- https://www.altesabio.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Altesa BioSciences addresses the challenge of developing safer and more effective therapeutic agents.
Solution
The company focuses on leveraging its proprietary technology to create innovative drug delivery systems.
Why now
There is a growing need for advanced therapeutic methods to improve patient outcomes in healthcare.
Verdict
Investors said yes at this moment largely due to the compelling narrative around advanced therapeutic methods and a clear focus on innovative drug delivery systems, which cleared because of the perceived urgency in healthcare needs, not simply because of a well-defined technology. They were implicitly betting on scaling proprietary technology to create safer drug delivery solutions, assuming those benefits would translate into substantial market demand. However, the limited upside stemmed from the intense competition in personalized medicine, which could quickly commoditize their innovations.
Source: SEC EDGAR Form D filing